WO1994006498A1 - Inhalateur - Google Patents

Inhalateur Download PDF

Info

Publication number
WO1994006498A1
WO1994006498A1 PCT/GB1993/002013 GB9302013W WO9406498A1 WO 1994006498 A1 WO1994006498 A1 WO 1994006498A1 GB 9302013 W GB9302013 W GB 9302013W WO 9406498 A1 WO9406498 A1 WO 9406498A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
medicament
inhalation device
air inlet
movement
Prior art date
Application number
PCT/GB1993/002013
Other languages
English (en)
Inventor
Michael Trevor Shepherd
Alastair Robert Clarke
Bruce James Renfrew
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220077A external-priority patent/GB9220077D0/en
Priority claimed from GB929220083A external-priority patent/GB9220083D0/en
Application filed by Fisons Plc filed Critical Fisons Plc
Priority to AU48295/93A priority Critical patent/AU4829593A/en
Publication of WO1994006498A1 publication Critical patent/WO1994006498A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws

Definitions

  • This invention relates to inhalation devices and in particular to devices for the inhalation of powdered medicament contained in capsules.
  • powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.
  • GB 1122284 discloses one such device for the inhalation of powdered medicament from a capsule, a preferred embodiment of this device is sold o under the name SPINHALERTM.
  • This device has the disadvantage that it must be dismantled for insertion of a capsule prior to inhalation and again to remove the empty capsule after inhalation. Dismantling the device can prove very difficult especially for those with impaired hand movement such as the elderly.
  • a medicament inhalation device including a housing defining a through-going pathway provided at one end with an air inlet, and at the other end with a mouthpiece; a drive member rotatably mounted in the housing on a shaft which is coaxial with the longitudinal axi o of the housing, the drive member having, on a portion adjacent to the air inlet, mounting means adapted to engage a medicament capsule, and the drive member being so mounted on the shaft that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member; characterised in that the air inlet is adapted to act as a capsule port through which a 5 capsule can be inserted into the mounting means.
  • the device according to the invention preferably includes release means to permit removal of a capsule from the mounting means through the air inlet. -.
  • Drive members suitable for use in the device according to the invention 0 include propellers having two or more rotor vanes or blades symmetrically disposed about a central axis or hub, such that impingement of an air stream on the rotor vanes or blades causes rotation of the propeller about the axis or hub.
  • the drive member preferably includes a sleeve-like bearing for mounting over the shaft of the device.
  • the drive member may be freely mounted on the shaft, however, we prefer the drive member to be retained on the shaft by retaining means
  • the retaining means may comprise a circumferential ridge formed on the interior wall of the sleeve-like bearing which is received by a circumferential recess formed on the shaft or vice versa.
  • the retaining means prevents the drive member falling of the shaft if the device needs to be dismantled, e.g. for cleaning.
  • the vibrational component of the movement of the drive member is essential for release of medicament from the capsule and to obtain constant and reproducible results from the inhalation device.
  • Vibrational movement of the drive member may be effected by controlling the dimensions of said member as described in GB 1122284 and GB 1301856 (Fisons pic) the disclosures of which are incorporated herein by reference.
  • the device according to the invention preferably includes piercing means for piercing a capsule held in the mounting means.
  • Suitable piercing mechanisms will b apparent to those skilled in the art and include e.g. pins or blades.
  • the piercing means preferably takes the form of one or more, e.g. two, spring biassed pins.
  • Piercing of the capsule may be effected by a cam surface moving over the spring biassed pins, the reciprocal movement of the cam surface allowing the pins to withdraw from the capsule under their spring bias.
  • cam surfaces these are preferably provided on the inside of a sleeve slidably mounted on the housing of the device.
  • the device may be used for dispensing medicament contained i pre-pierced capsules, i.e. capsules the walls of which are provided with one or more apertures during manufacture; in this case it is not necessary for the device to includ piercing means.
  • the air inlet of the device must be large enough to enable it to function as capsule port for the insertion of a medicament capsule into the mounting means.
  • the air inlet preferably comprises a circular aperture having a diameter slightly larger than the diameter of a capsule to be inserted into the mounting means.
  • the device may be provided with additional air inlets, for example, positioned radially around the capsule port air inlet.
  • the housing of the device may act to guide a capsule inserted through the air inlet into the mounting means, this may be achieved by providing a constriction in the housing between the air inlet and the mounting means. This constriction may .. also act to restrict the air stream which flows through the pathway upon inhalation b a patient at the mouthpiece, thus increasing the velocity of air past the capsule and aiding in the release of medicament therefrom.
  • the mounting means preferably includes resilient jaws adapted engage a medicament capsule.
  • the drive member includes rotor vanes these are preferably integrally moulded with the resilient jaws of the mounting means.
  • the device according to the invention preferably includes release means and mounting means including resilient jaws, wherein movement of the release means from a first position to a second position disengages the capsule from the mounting means. Movement of the release means from a first position to a second position may either move the jaws from an engaged to a disengaged position, or transport the capsule from an engaged to a disengaged position.
  • the release means When the drive member includes rotor vanes integrally moulded with the resilient jaws then movement of the release means from a first (rest) position to a second (release) position preferably urges the rotor vanes away from the air inlet thereby causing jaws to move from an engaged to a disengaged position.
  • the release means transports the capsule from an engaged to a disengaged position, the release means preferably includes an ejection arm which is adapted to urge the capsule out of the mounting means and through the air inlet. In a first (rest) position the ejection arm will be retracted from the mounting means an upon movement to a second (release) position will slide up inside the mounting means thereby ejecting the capsule. Movement of the ejection arm may be effected by an expulsion collar slidably mounted on the drive member.
  • the device according to the invention includes release means movement of the release means from a first to a second position is preferably effected by a sleeve slidably mounted on the housing.
  • the sleeve preferably performs the dual function of moving the release means and actuating piercing means. Therefore, in a preferred embodiment of the device, movement of the sleeve from a rest position in a direction parallel to the longitudinal axis of housing actuates piercing means for piercing a capsule held in the mounting means; and movement of the sleeve from the rest position in the opposite direction moves the release means from a first position to a second position.
  • the device comprises release means this is preferably biased into a - first position, i.e a rest position in which a capsule can be inserted into, and engaged by, the mounting means.
  • the device may, if desired, be fitted with a non-return valve so that air may only be inhaled and not blown through the device by the patient.
  • the device may be constructed of any suitable material, preferably of a synthetic thermoplastic resin, e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
  • a synthetic thermoplastic resin e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
  • the capsules for use with the device according to the invention are preferably cylindrical, they may be made from any material which can be pierced, e.g. gelatin.
  • the device may be used for dispensing any powdered medicament which is conventionally administered by inhalation to the lung or nose.
  • medicaments include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease.
  • Specific medicaments which may be mentioned include, for example, sodium cromoglycate and nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol; and salts thereof.
  • bronchodilators e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol
  • salts thereof e.g. salmeterol, salbutamol, reproterol, terbutaline,
  • Devices according to the invention have advantages over known inhalation devices in that the procedures for insertion of the medicament capsule into the device, and for removal of the empty capsule from the device after inhalation, are considerably simplified. Furthermore, since the device does not need to be dismantled for insertion/removal of the capsule, the patient is less likely to inadvertently injure themselves on the piercing means; and the propeller-like member, if freely mounted on the shaft, cannot fall off the shaft during the insertion/removal procedure.
  • Figure 1 is a perspective view of a device according to the invention.
  • Figure 2 is a longitudinal section of the device of Figure 1 in the rest position
  • Figure 3 is a section along the line III-III of Figure 2;
  • Figure 4 is a longitudinal section of the device of Figure 1 in the release position;
  • Figure 5 is a perspective view of an alternative device according to the invention.
  • Figure 6 is a longitudinal section of the device of Figure 5 in the rest position
  • Figure 7 is a section along the line VII- VII of Figure 6;
  • Figure 8 is a longitudinal section of the device of Figure 5 in the release position
  • a medicament inhalation device comprises a generally cylindrical housing (1) describing a through-going pathway.
  • the housing (1) is provided at one end with a mouthpiece portion (2), optionally having a removable mouthpiece cover (not shown), and provided at the other end with an air inlet (3).
  • a shaft (4) is rigidly mounted coaxially with the housing (1), the end of shaft (4) adjacent to the mouthpiece (2) end of housing (1) being supported by cross members (5).
  • Propeller (6) having a sleeve-like bearing (7) is mounted on shaft (4).
  • Shaft (4) is provided with a circumferential recess (8) which receives a circumferential ridge (9) formed on the interior wall of bearing (7) such that dissociation of the shaft (4) and the propeller (6) is prevented.
  • Propeller (6) is provided with a capsule mounting cup (10) comprising four resilient segments (11), shown best in Figure 3, which is adapted of engage a capsule (12) containing powdered medicament to be inhaled.
  • Propeller (6) is also provided with four rotor vanes (13) integrally moulded with segments (11), which cause the propeller (6) to rotate on shaft (4) when air is drawn through the pathway, as during inhalation. ..
  • Two stainless steel piercing needles (14), spring biased into the rest position s shown in Figures 2, are provided on housing (1).
  • One end of each needle (14) being secured to the housing (1), the other end being curved inwards such that they point towards a capsule (12) engaged by segments (11) of cup (10).
  • a sleeve (15) is slidably mounted on housing (1).
  • cam surfaces may be integrally moulded with the sleeve, however, for ease of manufacture they may be moulded separately and located in the sleeve during assembly of the device).
  • sleeve (15) turns inwards on itself thus s defining the walls of the air inlet (3).
  • Sleeve (15) extends further within housing (1) to form a circular release collar (17) which is located between the air inlet (3) and rotor vanes (13).
  • the collar (17) is adapted to apply downwards pressure onto rotor vanes (13) thus urging them away from the air inlet (3), thereby causing the segments (11) of cup 0 (10) to splay outwards.
  • the air inlet end of sleeve (15) urges needles (14) slightly inwards against their bias, this effect may be further enhanced by the provision of cam surfaces within the sleeve.
  • a capsule (12) containing powdered medicament to be inhaled is inserted through air inlet (3) and engaged by the segments (11) of cup (10).
  • Sleeve 5 (15) is then moved in the direction of arrow A in Figure 2 causing the cam surfaces
  • the patient then inhales through mouthpiece (2), thereby drawing air 0 through the pathway in the direction of arrow B in Figure 2.
  • the flow of air through the pathway causes the propeller (6) to rotate about shaft (4) and also to vibrate.
  • the medicament is thereby dispensed from capsule (12) through the apertures formed by needles (14), entrained in the air flow and inhaled by the patient.
  • the device is held with the air inlet (3) pointing downwards and sleeve (15) is moved over housing (1) in the direction of arrow C in Figure 4 (this may be achieved by pushing the sleeve and .. mouthpiece towards each other).
  • release collar (17) presses onto rotor vanes (13), s the pressure on rotor vanes (13) causing segments (11) to splay outwards from the base of cup (10) thus disengaging the empty capsule (12) which falls out of the housing (1) through the air inlet, as shown in Figure 4.
  • the sleeve (15) then returns to its rest position under the bias of needles (14) and the inhalation device is once more ready for use.
  • the release means includes a cylindrical ejection collar (18) slidably mounted around the housing (1).
  • the collar (18) is provided with projecting lugs (19) which cooperate with corresponding lugs (20) provided on the inside of sleeve (15).
  • Ejection collar (18) is also provided with two transverse arms (21) which project into housing (1). s Arms (21) abut against the base of a secondary ejection collar (22) slidably mounted around sleeve-like bearing (7). The secondary ejection collar (22) has two arms (23) running parallel to bearing (7) which extend through the base of mounting cup (10). Ejection collar (18) is biased into the rest position shown in Figure 6 by spring (24). In use, a capsule (12) containing medicament to be inhaled is inserted o through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve (15) is then moved in the direction of arrow D in Figure 6 causing the cam surfaces (16) to engage needles (14) and pierce capsule (12).
  • sleeve (15) is moved in the direction of arrow E in Figure 8, lugs (19, 20) slide the ejection collar (18) over housing (1) against the bias of spring 5 (24).
  • the arms (21) of the ejection collar (18) push the secondary ejection collar (22) up the bearing (4) and arms (23) are raised into cup (10) thereby ejecting the empty capsule (12) out of the housing (1) through the air inlet (23).
  • the sleeve (15) then returns to its rest position under the bias of spring (24) and the inhalation device is once more ready for use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inhalateur de médicament comprenant: un boîtier (1) définissant un passage traversant (1) muni à l'une des extrémités d'une entrée d'air (3), et à l'autre extrémité d'un embout buccal (2); et un organe d'entraînement (6) monté rotatif dans le boîtier (2) sur un arbre (4) qui est coaxial avec l'axe longitudinal du boîtier (1). L'organe d'entraînement (6) comporte, sur une partie adjacente à l'entrée d'air (3), un moyen de fixation (10) adapté pour venir en prise avec une capsule de médicament (12). Par ailleurs, l'organe d'entraînement (6) est monté sur l'arbre (4) de telle sorte que le passage d'un écoulement d'air dans le passage provoque le mouvement rotatif et vibrationnel de l'organe d'entraînement (6). L'invention est caractérisée en ce que l'entrée d'air (3) est adaptée pour agir comme un orifice à travers lequel on peut introduire une gélule (12) dans le moyen de fixation (10).
PCT/GB1993/002013 1992-09-23 1993-09-23 Inhalateur WO1994006498A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48295/93A AU4829593A (en) 1992-09-23 1993-09-23 Inhalation device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9220077.3 1992-09-23
GB929220077A GB9220077D0 (en) 1992-09-23 1992-09-23 Inhalation device
GB9220083.1 1992-09-23
GB929220083A GB9220083D0 (en) 1992-09-23 1992-09-23 Inhalation device

Publications (1)

Publication Number Publication Date
WO1994006498A1 true WO1994006498A1 (fr) 1994-03-31

Family

ID=26301671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002013 WO1994006498A1 (fr) 1992-09-23 1993-09-23 Inhalateur

Country Status (2)

Country Link
AU (1) AU4829593A (fr)
WO (1) WO1994006498A1 (fr)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755276A1 (fr) * 1994-04-14 1997-01-29 Dura Pharmaceuticals, Inc. Inhalateur a poudre seche
EP0796628A2 (fr) * 1996-03-21 1997-09-24 Unisia Jecs Corporation Inhalateur
WO1998030263A1 (fr) 1997-01-09 1998-07-16 Sepracor, Inc. Distributeur multidose pour inhalateur de poudre seche
US5947118A (en) * 1993-06-03 1999-09-07 Boehringer Ingelheim Kg Capsule holder
US5996577A (en) * 1995-08-11 1999-12-07 Unisia Jecs Corporation Medicine administering apparatus
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
WO2002024266A1 (fr) * 2000-09-25 2002-03-28 Microdrug Ag Dispositif de decoupe d'opercule
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
WO2005097175A2 (fr) 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
WO2007118858A1 (fr) * 2006-04-15 2007-10-25 Boehringer Ingelheim International Gmbh Inhalateur
WO2007118800A1 (fr) * 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Embout buccal pour inhalateur
WO2008021237A1 (fr) 2006-08-10 2008-02-21 Arubor Corporation Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire
US7456288B2 (en) 2003-10-28 2008-11-25 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
EP2090657A2 (fr) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
WO2009139733A1 (fr) * 2008-05-16 2009-11-19 Mahmut Bilgic Dispositif d'inhalation de poudre sèche
EP2123675A2 (fr) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations
EP2159230A1 (fr) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
WO2010051274A2 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
WO2010111485A1 (fr) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions permettant de stimuler la résistance immunitaire innée des mammifères contre les pathogènes
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
EP2253646A1 (fr) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anticorps anti intégrines doubles et compositions et conjugés les contenant
EP2308888A1 (fr) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP2452694A1 (fr) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
WO2012175735A1 (fr) 2011-06-23 2012-12-27 Vib Vzw Inhibiteurs d'a20 pour le traitement d'infections virales respiratoires
EP2548577A1 (fr) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Anticorps humains anti-IL-23, compositions, procédés et utilisations
US8481053B2 (en) 2002-02-13 2013-07-09 Immunology Laboratories, Inc. Compositions and methods for treating of microbial infections
WO2014106459A2 (fr) 2013-01-07 2014-07-10 Superlab Far East Limited Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée
WO2014135224A1 (fr) * 2013-03-08 2014-09-12 Interquim, S.A. Inhalateur
WO2014144763A2 (fr) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center Anticorps anti-gd2 à haute affinité
US8875701B2 (en) 2006-04-11 2014-11-04 Boehringer Ingelheim International Gmbh Inhaler
EP2842968A1 (fr) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, procédés et utilisations
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP3138601A1 (fr) * 2015-09-04 2017-03-08 Victor Esteve Inhalateur de poudre sèche
WO2018014039A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation
WO2018014038A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs antigéniques chimériques et leurs procédés d'utilisation
WO2018087699A2 (fr) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Méthodes et compositions pour une modulation immunitaire adaptative
EP3323830A1 (fr) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
WO2018112037A1 (fr) 2016-12-16 2018-06-21 Jia Zhou Inhibiteurs de protéine 4 contenant un bromodomaine (brd4)
WO2018115915A1 (fr) * 2016-12-20 2018-06-28 Emphasys Importadora Exportadora E Distribuidora Ltda. Inhalateur de poudre sèche
WO2018140026A1 (fr) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
EP1399105B2 (fr) † 2001-06-13 2018-09-05 Boehringer Ingelheim Pharma GmbH & Co.KG Procede pour nettoyer des capsules de gelatine dure
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2019126574A1 (fr) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions de vcar et méthodes d'utilisation
WO2019215701A1 (fr) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
WO2020148651A1 (fr) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
WO2020152544A1 (fr) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
WO2020183270A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020245677A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
WO2021211628A1 (fr) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions et méthodes destinées à être utilisées dans le traitement du cancer
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
WO2022026943A2 (fr) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales
US11389433B2 (en) 2018-06-18 2022-07-19 Board Of Regents, The University Of Texas System BRD4 inhibitor treatment of IgE-mediated diseases
WO2023279115A1 (fr) 2021-07-02 2023-01-05 Henry Ford Health System COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
WO2023281463A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
EP4190817A1 (fr) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anticorps anti-muc16 et leurs utilisations
EP3986514A4 (fr) * 2019-06-24 2023-08-09 De Motu Cordis Pty Ltd Distributeur automatique pour dispositif d'administration respiratoire
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US12109356B2 (en) 2019-06-24 2024-10-08 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device and method
US12122825B2 (en) 2020-02-26 2024-10-22 Janssen Biotech, Inc. Nucleic acid molecule encoding, and method of producing, a recombinant anti-tumor necrosis factor (TNF) antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH461035A (fr) * 1966-09-17 1968-08-15 Fisons Pharmaceuticals Ltd Appareil pour l'inhalation orale de médicaments sous forme finement divisée
GB1268051A (en) * 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
FR2380032A1 (fr) * 1977-02-10 1978-09-08 Allen & Hanburys Ltd Inhalateur a capsules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH461035A (fr) * 1966-09-17 1968-08-15 Fisons Pharmaceuticals Ltd Appareil pour l'inhalation orale de médicaments sous forme finement divisée
GB1268051A (en) * 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
FR2380032A1 (fr) * 1977-02-10 1978-09-08 Allen & Hanburys Ltd Inhalateur a capsules

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5947118A (en) * 1993-06-03 1999-09-07 Boehringer Ingelheim Kg Capsule holder
EP0755276A4 (fr) * 1994-04-14 1998-04-01 Dura Pharma Inc Inhalateur a poudre seche
EP0755276A1 (fr) * 1994-04-14 1997-01-29 Dura Pharmaceuticals, Inc. Inhalateur a poudre seche
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US5996577A (en) * 1995-08-11 1999-12-07 Unisia Jecs Corporation Medicine administering apparatus
EP0796628A2 (fr) * 1996-03-21 1997-09-24 Unisia Jecs Corporation Inhalateur
EP0796628A3 (fr) * 1996-03-21 1998-05-06 Unisia Jecs Corporation Inhalateur
WO1998030263A1 (fr) 1997-01-09 1998-07-16 Sepracor, Inc. Distributeur multidose pour inhalateur de poudre seche
US5794613A (en) * 1997-01-09 1998-08-18 Sepracor, Inc. Multiple-dose dispenser for dry powder inhalers
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
EP2330129A2 (fr) 2000-08-07 2011-06-08 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
EP3118318A1 (fr) 2000-08-07 2017-01-18 Janssen Biotech, Inc. Anticorps anti-tnf, compositions, procédés et utilisations
EP2305817A2 (fr) 2000-08-07 2011-04-06 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
EP2253646A1 (fr) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anticorps anti intégrines doubles et compositions et conjugés les contenant
EP3597752A1 (fr) 2000-08-07 2020-01-22 Janssen Biotech, Inc. Anticorps anti-il-12, compositions, procédés et utilisations
EP2090657A2 (fr) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anticorps anti-IL-12, compositions, procédés et utilisations
EP2159230A1 (fr) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anticorps anti-TNF, compositions, procédés et utilisations
WO2002024266A1 (fr) * 2000-09-25 2002-03-28 Microdrug Ag Dispositif de decoupe d'opercule
EP1399105B2 (fr) † 2001-06-13 2018-09-05 Boehringer Ingelheim Pharma GmbH & Co.KG Procede pour nettoyer des capsules de gelatine dure
EP2308888A1 (fr) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
US9539292B2 (en) 2002-02-13 2017-01-10 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9962434B2 (en) 2002-02-13 2018-05-08 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8481053B2 (en) 2002-02-13 2013-07-09 Immunology Laboratories, Inc. Compositions and methods for treating of microbial infections
US9241984B2 (en) 2002-02-13 2016-01-26 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9511101B2 (en) 2002-02-13 2016-12-06 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8518416B2 (en) 2002-02-13 2013-08-27 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9072694B2 (en) 2002-02-13 2015-07-07 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8920815B2 (en) 2002-02-13 2014-12-30 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
EP2123675A2 (fr) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Mimétiques de l'EPO humaine à région centrale à charnière, compositions, procédés et utilisations
US7456288B2 (en) 2003-10-28 2008-11-25 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
WO2005097175A2 (fr) 2004-03-31 2005-10-20 Centocor, Inc. Corps mimetiques glp-1 humains, compositions, procedes et utilisations
EP2842968A1 (fr) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, procédés et utilisations
EP3501537A1 (fr) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anticorps anti-il23, compositions, procédés et utilisations
EP2452694A1 (fr) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
EP3219328A1 (fr) 2005-12-29 2017-09-20 Janssen Biotech, Inc. Compositions, procédés et utilisations d'anticorps humains anti-il-23
EP2548577A1 (fr) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Anticorps humains anti-IL-23, compositions, procédés et utilisations
EP3760230A1 (fr) 2005-12-29 2021-01-06 Janssen Biotech, Inc. Anticorps humains anti-il-23, compositions, procédés et utilisations
JP2009533112A (ja) * 2006-04-11 2009-09-17 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 吸入器用マウスピース
US8875701B2 (en) 2006-04-11 2014-11-04 Boehringer Ingelheim International Gmbh Inhaler
WO2007118800A1 (fr) * 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Embout buccal pour inhalateur
EP2656867A3 (fr) * 2006-04-11 2014-01-22 Boehringer Ingelheim Pharma GmbH & Co. KG Embouchure pour un inhalateur
US8281784B2 (en) 2006-04-11 2012-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mouthpiece for an inhaler
US8196578B2 (en) 2006-04-15 2012-06-12 Boehringer Ingelheim International Gmbh Inhaler
JP2009533192A (ja) * 2006-04-15 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
WO2007118858A1 (fr) * 2006-04-15 2007-10-25 Boehringer Ingelheim International Gmbh Inhalateur
EP3669878A1 (fr) 2006-08-10 2020-06-24 Roy C. Levitt Thérapie localisée des troubles inflammatoires des voies respiratoires inférieures avec des inhibiteurs de cytokines inflammatoires
WO2008021237A1 (fr) 2006-08-10 2008-02-21 Arubor Corporation Thérapie locale de troubles inflammatoires des voies aériennes inférieures avec des inhibiteurs de cytokine proinflammatoire
US11718853B2 (en) 2006-08-10 2023-08-08 Onspira Therapeutics, Inc. Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
WO2009139733A1 (fr) * 2008-05-16 2009-11-19 Mahmut Bilgic Dispositif d'inhalation de poudre sèche
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
WO2010051274A2 (fr) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Compositions d'échafaudage à base de domaines de la fibronectine de type iii, procédés et utilisations
EP3128048A1 (fr) 2008-10-31 2017-02-08 Janssen Biotech, Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
WO2010093627A2 (fr) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
US10722573B2 (en) 2009-03-25 2020-07-28 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9186400B2 (en) 2009-03-25 2015-11-17 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9504742B2 (en) 2009-03-25 2016-11-29 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010111485A1 (fr) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions permettant de stimuler la résistance immunitaire innée des mammifères contre les pathogènes
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
EP3323830A1 (fr) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
EP4269563A2 (fr) 2010-06-19 2023-11-01 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
WO2012175735A1 (fr) 2011-06-23 2012-12-27 Vib Vzw Inhibiteurs d'a20 pour le traitement d'infections virales respiratoires
EP3895725A2 (fr) 2013-01-07 2021-10-20 Superlab Far East Limited Procédé de traitement de tumeurs au moyen d'interféron recombinant à configuration spatiale modifiée
WO2014106459A2 (fr) 2013-01-07 2014-07-10 Superlab Far East Limited Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée
WO2014135224A1 (fr) * 2013-03-08 2014-09-12 Interquim, S.A. Inhalateur
WO2014144763A2 (fr) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center Anticorps anti-gd2 à haute affinité
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP4190817A1 (fr) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anticorps anti-muc16 et leurs utilisations
EP3138601A1 (fr) * 2015-09-04 2017-03-08 Victor Esteve Inhalateur de poudre sèche
WO2018014039A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation
WO2018014038A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs antigéniques chimériques et leurs procédés d'utilisation
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
WO2018087699A2 (fr) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Méthodes et compositions pour une modulation immunitaire adaptative
US11117865B2 (en) 2016-12-16 2021-09-14 Board Of Regents, The University Of Texas System Inhibitors of bromodomain-containing protein 4 (BRD4)
WO2018112037A1 (fr) 2016-12-16 2018-06-21 Jia Zhou Inhibiteurs de protéine 4 contenant un bromodomaine (brd4)
US11517686B2 (en) 2016-12-20 2022-12-06 Emphasys Importadora Exportadora E Distribuidora Ltda. Dry powder inhaler
WO2018115915A1 (fr) * 2016-12-20 2018-06-28 Emphasys Importadora Exportadora E Distribuidora Ltda. Inhalateur de poudre sèche
WO2018140026A1 (fr) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2019126574A1 (fr) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions de vcar et méthodes d'utilisation
WO2019215701A1 (fr) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
US11389433B2 (en) 2018-06-18 2022-07-19 Board Of Regents, The University Of Texas System BRD4 inhibitor treatment of IgE-mediated diseases
WO2020148651A1 (fr) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et procédés pour le traitement de l'arthrite idiopathique juvénile
WO2020152544A1 (fr) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
WO2020183270A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183271A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2020245677A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3986514A4 (fr) * 2019-06-24 2023-08-09 De Motu Cordis Pty Ltd Distributeur automatique pour dispositif d'administration respiratoire
US12109356B2 (en) 2019-06-24 2024-10-08 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device and method
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
US12129292B2 (en) 2020-02-26 2024-10-29 Janssen Biotech, Inc. Anti-tumor necrosis factor (TNF) antibodies and compositions thereof
US12122825B2 (en) 2020-02-26 2024-10-22 Janssen Biotech, Inc. Nucleic acid molecule encoding, and method of producing, a recombinant anti-tumor necrosis factor (TNF) antibody
WO2021211628A1 (fr) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions et méthodes destinées à être utilisées dans le traitement du cancer
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
WO2022026943A2 (fr) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Peptides de fusion de la neuropiline et de l'enzyme de conversion de l'angiotensine 2 pour le traitement d'infections virales
US12122824B2 (en) 2021-05-14 2024-10-22 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2023279115A1 (fr) 2021-07-02 2023-01-05 Henry Ford Health System COMPOSITIONS COMPRENANT DE L'ENDOSIDINE 2 POUR RÉDUIRE UNE INFECTION À SARS-CoV-2
WO2023281463A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf

Also Published As

Publication number Publication date
AU4829593A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
WO1994006498A1 (fr) Inhalateur
KR100321814B1 (ko) 건분말흡입기
US5787881A (en) Inhalation device
KR0177265B1 (ko) 건분말 흡입기
KR100218816B1 (ko) 분말 흡입기
RU2393883C1 (ru) Простой ингалятор
KR100323942B1 (ko) 의약흡입기및흡입방법
RU2332240C2 (ru) Магазин-дозатор с предварительным отмериванием для ингалятора сухого порошкообразного средства
US5243970A (en) Dosing device for administering metered amounts of powdered medicaments to patients
JP5651233B2 (ja) 簡易なカプセル・ベースの吸入器
FI67026C (fi) Andningsaktiverad anordning foer oral inhalation av pulverformiga laekemedel
US4116195A (en) Device for dispensing medicaments
US9050427B2 (en) Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods
JP6946363B2 (ja) 吸入可能な薬剤
JPH04227269A (ja) 粉末薬物の投与器具
JPH08509626A (ja) 吸入装置
WO2007093310A2 (fr) Améliorations apportées à des dispositifs inhalateurs de poudre sèche ou les concernant
JPH0147190B2 (fr)
JP2001524363A (ja) 乾燥粉末吸入器
JPH08103499A (ja) 吸入式投薬器
JPH06509958A (ja) 粉末ディスペンサ
US20130025593A1 (en) Dry powder inhaler
JPH05505738A (ja) 薬剤吸入装置
WO2002089875A1 (fr) Dispositif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642